PubMed Central (PMC) Search Page
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 20 |
| 2009 | 26 |
| 2010 | 25 |
| 2011 | 31 |
| 2012 | 32 |
| 2013 | 25 |
| 2014 | 121 |
| 2015 | 133 |
| 2016 | 962 |
| 2017 | 116 |
| 2018 | 123 |
| 2019 | 76 |
| 2020 | 82 |
| 2021 | 95 |
| 2022 | 216 |
| 2023 | 86 |
| 2024 | 73 |
| 2025 | 1146 |
| 2026 | 572 |
-
Publication date
-
-
Publication stage
These filters represent the three primary types of content included in the PMC archive: 1) content published in a scholarly journal 2) peer-reviewed author manuscripts accepted for publication in a journal and 3) preprint versions of articles collected through the NIH Preprint Pilot, made public prior to peer review
-
-
Collections
The PMC Open Access Subset includes journal articles and preprints that are made available under license terms that allow reuse. Historical back issues refers to digitized content from print journals made available in PMC through the Biomedical Journal Digitization Projects.
-
"Int J Neuropsychopharmacol"[Journal]
The embargo is the time during which the publisher retains exclusive rights to distribute articles. Those articles are made freely available on the PMC website after the embargo period has ended. Citations for articles under an embargo period will still display in the PMC results list by default. Choose “Exclude” to prevent embargoed articles from displaying in your results.
-
Divergent effects of interleukin-6 and ghrelin on remission and relapse in depression treatment.
- Kim JM, Kang HJ, Kim JW, Jhon M, Lee JY, Kim SW, Shin IS.
- Int J Neuropsychopharmacol. 2026 Oct 8;29(10):pyag032. doi: 10.1093/ijnp/pyag032.
- PMCID: PMC13688350
Kim JM, et al.Int J Neuropsychopharmacol. 2026.PMCID: PMC13688350 -
Disruption of ultrasonic vocalizations with systemic administration of the non-competitive N-methyl-D-aspartate receptor antagonist MK-801 in adult male mice.
- Tamura R, Yamamoto M, Ujihara Y, Kasahara H, Matsushima S, Nasukawa D, Hayashi K, Yamada K, Tanaka M, Toda K.
- Int J Neuropsychopharmacol. 2026 Oct 8;29(10):pyag048. doi: 10.1093/ijnp/pyag048.
- PMCID: PMC13647287
Tamura R, et al.Int J Neuropsychopharmacol. 2026.PMCID: PMC13647287 -
From depression to bone health: examining the skeletal effects of classical and rapid-acting antidepressants.
- Louka P, Pitsillides AA, Koumas M, Papacharalambous C, Sophocleous A, Zanos P.
- Int J Neuropsychopharmacol. 2026 Sep 1;29(9):pyag044. doi: 10.1093/ijnp/pyag044.
- PMCID: PMC13589849
Louka P, et al.Int J Neuropsychopharmacol. 2026.PMCID: PMC13589849 -
Vornorexant versus lemborexant for insomnia disorder: a systematic review and network meta-analysis.
- Kishi T, Sakuma K, Kitajima T, Iwata N.
- Int J Neuropsychopharmacol. 2026 Sep 1;29(9):pyag047. doi: 10.1093/ijnp/pyag047.
- PMCID: PMC13580082
Kishi T, et al.Int J Neuropsychopharmacol. 2026.PMCID: PMC13580082 -
Parvalbumin interneurons under stress: converging mechanisms of vulnerability.
- Santos-Silva T, Godoy LD, Guimarães FS, Gomes FV.
- Int J Neuropsychopharmacol. 2026 Sep 1;29(9):pyag043. doi: 10.1093/ijnp/pyag043.
- PMCID: PMC13561109
Santos-Silva T, et al.Int J Neuropsychopharmacol. 2026.PMCID: PMC13561109 -
Chronic social defeat stress induces a hypoglycemic shift and depression-related behaviors, both prevented by antidiabetic drugs.
- Qiu W, Nagai H, Ota K, Nagai M, Furuyashiki T.
- Int J Neuropsychopharmacol. 2026 Sep 1;29(9):pyag046. doi: 10.1093/ijnp/pyag046.
- PMCID: PMC13557117
Qiu W, et al.Int J Neuropsychopharmacol. 2026.PMCID: PMC13557117 -
Multiomic single-nucleus profiling reveals cell-type-specific epigenetic and transcriptional dysregulation in major depressive disorder brain.
- Francis A, Dwivedi Y.
- Int J Neuropsychopharmacol. 2026 Sep 1;29(9):pyag045. doi: 10.1093/ijnp/pyag045.
- PMCID: PMC13557119
Francis A, et al.Int J Neuropsychopharmacol. 2026.PMCID: PMC13557119 -
195. Healthcare resource utilization among adult patients with focal-onset seizures using cenobamate: a US database analysis.
- Lovera A.
- Int J Neuropsychopharmacol. 2026 Sep 9;29(Suppl 1):i105. doi: 10.1093/ijnp/pyag040.192.
- PMCID: PMC13556710
Lovera A.Int J Neuropsychopharmacol. 2026.PMCID: PMC13556710 -
582. Predicting psychiatric symptom deterioration using heart rate variability: the role of temporal feature engineering.
- Kim MK, Min SY, Ahn YM.
- Int J Neuropsychopharmacol. 2026 Sep 9;29(Suppl 1):i195-6. doi: 10.1093/ijnp/pyag040.360.
- PMCID: PMC13556367
Kim MK, et al.Int J Neuropsychopharmacol. 2026.PMCID: PMC13556367 -
485. Exploring the interactive effects of ADH1B and ALDH2 genes on drinking outcomes following 12 weeks of naltrexone treatment in patients with alcohol use disorder.
- Jhang L, Meng SC, Huang MC.
- Int J Neuropsychopharmacol. 2026 Sep 9;29(Suppl 1):i176-7. doi: 10.1093/ijnp/pyag040.325.
- PMCID: PMC13556488
Jhang L, et al.Int J Neuropsychopharmacol. 2026.PMCID: PMC13556488